tradmap

TLSI Earnings TriSalus Life Sciences, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$162 -$81 $0 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $23M $45M 2021 2022 2023 2024 2025
Revenue
Net income (annual)
-$59M -$27M $5M $0 2021 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$82 -$41 $0 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Revenue (quarterly)
$0 $7M $13M Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
-$36M -$17M $2M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–16 of 16
Q2 20262026-06-30-0.142026-08-0610-Q
Q1 20262026-03-310.032026-05-1210-Q
FY 20252025-12-31-1.842026-03-0510-K
Q3 20252025-09-30-1.722025-11-1310-Q
Q2 20262025-06-30-0.652026-08-0610-Q
Q1 20262025-03-31-0.392026-05-1210-Q
FY 20252024-12-31-1.312026-03-0510-K
Q3 20252024-09-30-0.912025-11-1310-Q
Q2 20252024-06-30-0.812025-08-1210-Q
Q1 20252024-03-31-0.602025-05-1510-Q
FY 20242023-12-31-6.772025-04-1510-K
Q3 20242023-09-30-5.722024-11-1410-Q
Q2 20242023-06-30-59.792024-08-1410-Q
Q1 20242023-03-31-0.572024-05-1510-Q
FY 20232022-12-31-161.552024-04-1110-K
Q3 20232022-09-30-82.172023-11-1410-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.